Balyasny Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Balyasny Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-262,500	Closed	-$7.99M	–	2646
2021 Q4	$7.99M	Buy	262,500 +112,500	+75%	+$3.54M	0.03%	700
2021 Q3	$5.03M	Buy	+150,000	New	+$5.65M	0.02%	817
2018 Q4	–	Sell	-57,000	Closed	-$2.85M	–	1549
2018 Q3	$2.85M	Buy	+57,000	New	+$2.68M	0.01%	879
2018 Q1	–	Sell	-250,000	Closed	-$12.6M	–	2111
2017 Q4	$12.6M	Buy	250,000 +50,000	+25%	+$2.74M	0.04%	560
2017 Q3	$10.1M	Buy	+200,000	New	+$10.5M	0.04%	504
2017 Q1	–	Sell	-140,000	Closed	-$6.7M	–	1678
2016 Q4	$6.7M	Buy	+140,000	New	+$5.54M	0.04%	608

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's IONS Position: Q1 2026 in Review

Balyasny Asset Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2026, closing a stake of 120,577 shares — an estimated $9.54M sold.

Balyasny Asset Management first reported a position in IONS in Q4 2015 and held it in 16 quarters. The position peaked at $51.3M in Q2 2024. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Balyasny Asset Management reported no remaining Ionis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Balyasny Asset Management sold 120,577 Ionis Pharmaceuticals shares in Q1 2026, an estimated $9.54M.
Balyasny Asset Management first reported a position in Ionis Pharmaceuticals in Q4 2015 and held it in 16 quarters.
Balyasny Asset Management's Ionis Pharmaceuticals position peaked at $51.3M in Q2 2024.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.